| 1 |
Review Innovative vaccine production technologies: the evolution and value of vaccine production technologies. 2009
Bae K, Choi J, Jang Y, Ahn S, Hur B. · Vaccine Research Institute, CrucellBerna Biotech Korea, Yongin, 449-903, Korea. · Arch Pharm Res. · Pubmed #19407962 No free full text.
Abstract: This review paper provides an overview of innovative technologies designed to produce bacterial, viral, recombinant subunit, and polysaccharide vaccines, as well as combination vaccines. Advances in this field are illustrated by vaccines against DTP (diphtheria-tetanus-pertussis), influenza, hepatitis B (HepB) and typhoid fever. In addition, technological trends regarding antigens, adjuvants, and preservatives in vaccines are discussed. The progress achieved in vaccine production technologies is especially important for improving the protection of vulnerable populations against infectious diseases. These at-risk groups include infants, the elderly and immunocompromized individuals, as well as people living in developing countries or emerging economies.
|
| 2 |
Article Severe hepatotoxicity after sevoflurane anesthesia in a child with mild renal dysfunction. 2005
Jang Y, Kim I. · Department of Anesthesiology and Pain Medicine, School of Medicine, Keimyung University, Daegu, Korea. · Paediatr Anaesth. · Pubmed #16324041 No free full text.
Abstract: Sevoflurane, an anesthetic agent with methyl isopropyl fluorinated ether structure, has a very low potential for hepatotoxicity. Nevertheless, a few cases of hepatotoxicity have been reported since its introduction into clinical practice. The underlying pathophysiology may be multifactorial and sometimes nonspecific. We report a case of severe hepatotoxicity after anesthesia with sevoflurane in a child with preexisting mild renal dysfunction.
|